Barcelona Liver Bioservices (BLB) expands its translational liver research portfolio with a microfluidic human cirrhotic liver slice platform designed to model advanced chronic liver disease ex vivo. This technology supports the study of fibrosis mechanisms and the preclinical evaluation of antifibrotic therapies in human liver tissue.

Barcelona Liver Bioservices announces the oral presentation of a study using microfluidic human liver slices, revealing the antifibrotic effects of liraglutide through hepatic stellate cell deactivation and extracellular matrix remodeling.

Washington DC, November 7th 2025 Barcelona Liver Bioservices (BLB), a leading preclinical research organization specialized in liver disease modeling and drug discovery, is proud to